HEPATOCELLULAR CARCINOMA KINOME ATLAS AS AN EMPLOYABLE INSTRUMENTED PERSONALIZED MEDICINE

Liver cancer ranks high among cancer death rates and is resistant to most therapies. Studies of protein functionality are limited in patients with hepatocellular carcinoma (HCC). Here, we constructed an HCC kinome activity atlas and used it to develop personalized medicine technology applicable to profiling protein functionality. We used PamGene PamStation kinome technology that quantified protein kinase activity across hundreds of pathways for HCC tumor and non-tumor regions from both sexes. According to our bioinformatic analyses of kinases, ABL was the most active for men and women with HCC. Next, we employed three ABL inhibitors while running the PamStation, which revealed discernible alterations in ABL and other pathways. We deconvoluted over 500 kinase pathways and generated a personalized medicine (PerMed) score delineating activity levels; results were substantiated in five human hepatocyte cancer cell lines. Our work establishes an HCC kinome atlas and demonstrates PamStations potential for precision medicine applications.